Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets.
| Revenue (Most Recent Fiscal Year) | $564.17M |
| Net Income (Most Recent Fiscal Year) | $37.03M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 74.67 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.56 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.18 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.46 |
| Pre-Tax Margin (Trailing 12 Months) | 0.83% |
| Net Margin (Trailing 12 Months) | -0.84% |
| Return on Equity (Trailing 12 Months) | 9.63% |
| Return on Assets (Trailing 12 Months) | 4.76% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.53 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.16 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.05 |
| Inventory Turnover (Trailing 12 Months) | 4.27 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.36 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.19 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 128.68M |
| Free Float | 86.21M |
| Market Capitalization | $288.23M |
| Average Volume (Last 20 Days) | 1.36M |
| Beta (Past 60 Months) | 1.32 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 33.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 49.57% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |